biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Market Trends Global Forecasts Report 2025: A Obesity Drugs Boom: GLP-1 Competitors

Explore methods, challenges, and clinical implications for personalized treatment.

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Significance statement ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest

GLP-1 receptor agonist clinical trials surge, with semaglutide leading the way in obesity and type 2 diabetes treatmen

PlexusDx provides compounded semaglutide and tirzepatide injections with clear guidance to help you feel confident with every dose

This helps to increase insulin release after eating, lower glucagon levels, and slow down the emptying of the stomach, all of which contribute to improved blood sugar levels